Tybourne Capital Management

Tybourne Capital Management is a Hong Kong-based global growth investment firm founded in 2012. It manages long-term capital on behalf of institutional and high-net-worth clients. The firm invests across public and private markets globally with a strong focus on healthcare, technology, consumer, and financials. In recent years it has shifted away from public market hedge funds to concentrate on long-only and private investments. Its healthcare portfolio includes significant stakes in biopharmaceutical and medical technology companies such as Zentalis Pharmaceuticals/Zentera Therapeutics, WuXi Biologics, Tigermed, SK Biopharmaceuticals, Lunit (medical AI), Acelyrin Inc., Taysha Gene Therapies Inc., Bicycle Therapeutics plc, Forte Biosciences Inc., among others[1][6][7][8][9].